Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × avelumab × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 6 Genitourinary 6 Thoracic 5 Gastrointestinal 3 Head & Neck 2 Gynecologic 2 Breast 2 Sarcoma 1 NET 1 Endocrine 1 Dermatologic 1 CNS 1

Conditions

Neuroendocrine Tumors 4 Carcinoma, Merkel Cell 2 Neoplasms 1 Carcinoma, Neuroendocrine 1 Carcinoma 1

Interventions

Everolimus 5 Sunitinib 4 lutetium Lu 177 dotatate 2 PM 01183 2 Octreotide 2 Doxorubicin 2 telotristat ethyl 1 repotrectinib 1 pralsetinib 1 pasireotide 1 motesanib diphosphate 1 epothilone B 1 dactolisib 1 copper dotatate CU-64 1 batifiban 1 avelumab 1 Surveys and Questionnaires 1 SNX-5422 1 Referral and Consultation 1 Radiomics 1 Oxaliplatin 1 Lutetium-177 1 Lutetium 1 Leucovorin 1 Irinotecan 1 Injections 1 Fluorouracil 1 Embolization, Therapeutic 1 Cytidine Triphosphate 1 Chemoembolization, Therapeutic 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03352934 2022-02-25

AveNEC

Johannes Gutenberg University Mainz

Phase 2 Completed

Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡